We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$473M
Cap. Flow %
-6.14%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Miscellaneous 11.22%
3 Financials 0.64%
4 Consumer Staples 0.2%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX
26
DELISTED
Crinetics Pharmaceuticals
CRNX
$74.7M 0.97%
3,963,517
+304,136
+8% +$5.34M
RLAY icon
27
Relay Therapeutics
RLAY
$4.16B
$73.8M 0.96%
2,018,097
– –
BEAM icon
28
Beam Therapeutics
BEAM
$2.4B
$69.2M 0.9%
537,635
– –
ZY
29
DELISTED
Zymergen Inc. Common Stock
ZY
$65.3M 0.85%
+1,633,332
New +$64.5M
CHRS icon
30
Coherus Oncology
CHRS
$205M
$65M 0.84%
4,697,612
– –
ATNX
31
DELISTED
Athenex, Inc. Common Stock
ATNX
$62.5M 0.81%
676,623
– –
ESTA icon
32
Establishment Labs
ESTA
$2.13B
$61.2M 0.79%
700,408
-286,879
-29% -$21.3M
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
$60.8M 0.79%
15,711,334
– –
KRON
34
DELISTED
Kronos Bio
KRON
$60.5M 0.79%
2,528,052
-252,045
-9% -$6.38M
QTNT
35
DELISTED
Quotient Limited Ordinary Shares
QTNT
$59M 0.77%
405,020
– –
MGNX icon
36
MacroGenics
MGNX
$257M
$57.7M 0.75%
2,148,060
– –
MDT icon
37
Medtronic
MDT
$120B
$55.9M 0.72%
+450,000
New +$56.5M
MORF
38
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$53.8M 0.7%
938,140
– –
SLDB icon
39
Solid Biosciences
SLDB
$897M
$49.1M 0.64%
894,170
– –
AVIR icon
40
Atea Pharmaceuticals
AVIR
$419M
$48.5M 0.63%
2,259,224
-850,000
-27% -$25.5M
CMAX
41
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$42.8M 0.56%
110,667
+110,000
+16,492% +$43.7M
DBVT
42
DBV Technologies
DBVT
$739M
$42M 0.55%
769,551
– –
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$41.8M 0.54%
+661,162
New +$34.1M
VRCA icon
44
Verrica Pharmaceuticals
VRCA
$78.7M
$40.8M 0.53%
361,041
– –
RAIN
45
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$39.4M 0.51%
+2,537,019
New +$44.5M
TMCI icon
46
Treace Medical Concepts
TMCI
$298M
$38.6M 0.5%
+1,235,886
New +$39.3M
TARS icon
47
Tarsus Pharmaceuticals
TARS
$3.66B
$37.6M 0.49%
1,296,416
– –
AXSM icon
48
Axsome Therapeutics
AXSM
$10.7B
$37.4M 0.48%
+553,908
New +$33.2M
VERU icon
49
Veru
VERU
$39.9M
$35.9M 0.47%
445,134
– –
LONA
50
LeonaBio Inc
LONA
$68.2M
$35.1M 0.46%
342,592
– –
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.